The Use of Corticosteroid Treatment Protocols in Compressive Epidural Spinal Metastases: Current Practice and the Need for Consensus.

Spine (Phila Pa 1976)May 28, 2026 (epub)
Clinical ResearchOncology (Medical)

Kathleen S Botterbush, Mayur S Patel, Advika N Srinivas et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated corticosteroid treatment protocols in patients with compressive epidural spinal metastases. It analyzed 39 studies and found that post-1997, survival outcomes improved significantly, with a higher proportion of patients ambulating pretreatment (42.11% vs 70.59%; P <0.0001). Despite these findings, consensus on optimal corticosteroid use remains lacking.

Key findings

  • Survival outcomes were significantly higher post-1997 at all time frames.
  • The proportion of patients ambulating pretreatment increased significantly over time (42.11% vs 70.59%; P <0.0001).
  • Adverse effects from steroid treatment were significantly higher pre-1997 (P <0.0001).
  • Recent studies suggest a dexamethasone dosage of 12 to 32 mg/day.

Why it matters

Understanding corticosteroid protocols is crucial for managing patients with compressive spinal metastases, as timely and appropriate treatment can influence survival and ambulation outcomes. The lack of consensus highlights the need for standardized guidelines.

Source

Published in Spine (Phila Pa 1976). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.